Reading DOCS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DOCS free→Reading DOCS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DOCS free→NYSEHealth CareHealth Information ServicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but risk is high and the sector backdrop is a headwind. Earnings quality and management's recent track record are neutral, while the capital stance is capital-friendly. Peer multiples imply a price about 7% below where it trades (it looks expensive on this basis); the read is fair, priced roughly in line with peer multiples. Key factors to watch include guidance changes and sector trends, as these could significantly impact performance. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $20.90. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $21 DOCS trades at 14× p/e, below its 16× p/e peer median. Our $19 fair value sits above the price; high confidence. Analysts: $18–$42. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 7% near-term growth, in line with our forecast of about 12%. This describes what's priced in, not a forecast of the move.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.67x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.35 → $0.30 (-12.4% / 30d). 0 raised, 13 cut, 18 covering analysts.
0 upgrades, 0 downgrades / 30d. 43% of analysts rate Buy.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$160.
How much price usually moves either way.
On a bad day, this stock has moved -$522.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,603.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This guidance shows if Doximity can keep growing revenue as planned. Strong guidance signals confidence.
Confirms:Revenue guidance meets or exceeds $152 million.
Disproves:Revenue guidance falls below $151 million.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
AI spending pressure could hinder revenue growth.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On May 13, 2026, Doximity, Inc. (the “Company”) announced the appointment of Matthew Sonefeldt as Chief Financial Officer of the Company, effective May 13, 2026. In connection with this appointment, Siddharth Sitaram, Chief Accounting Officer, will continue to serve as the Company’s interim Principal Financial Officer through June 7, 2026. Mr. Sonefeldt will formally succeed Mr. Sitaram as t…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$18.00 – $42.00 (median $25.50) · 16 analysts · as of 2026-05-14
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
DOCS Doximity | Above typical Show detailsSector percentile: 80 of 100 | full | high |
VEEV Veeva Systems | Above typical Show detailsSector percentile: 79 of 100 | full | elevated |
SOLV Solventum | Above typical Show detailsSector percentile: 75 of 100 | fair | moderate |
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 72 of 100 | — | elevated |
TXG 10X Genomics, Inc. | Typical Show detailsSector percentile: 47 of 100 | expensive | elevated |
4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain revenue growth with guidance for fiscal year ending March 31, 2027.
Manage the transition of the Chief Financial Officer position effectively.
Implement a share buyback program to enhance shareholder value.
Why it matters: Revenue growth guidance will show if Doximity can keep expanding. This is key for investors.
Confirms:Management raises revenue growth forecast to more than 10%.
Disproves:Management lowers revenue growth forecast to less than 8%.
Why it matters: This number shows how well Doximity controls costs and grows revenue. Strong EBITDA guidance shows good operations.
Confirms:Adjusted EBITDA guidance is $69.5 million or more.
Disproves:Adjusted EBITDA guidance is less than $68.5 million.
Why it matters: The new CFO's approach can affect financial guidance and investor confidence. This is crucial for future growth.
Confirms one read:The new CFO provides a positive outlook and maintains or raises guidance.
Confirms the other:The new CFO issues cautious guidance or lowers expectations.
Leadership shift and AI focus may enhance growth outlook.
of this Current Report on Form 8-K, and the Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers As previously disclosed by Doximity, Inc. (the “Company”) on February 5, 2026, Anna Bryson, the Company’s Chief Financial Officer, had been on medical leave. On April 13, 2026, the Company accepted her resignation as Chief Financial Officer. Effective February 3, 2026, the Company’s Board of Directors appointed Siddharth Sitaram, the Company’s Chief Accounting Officer, to serve as the Compan…
of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Use of Forward-Looking Statements Statements we make in this Current Report on Form 8-K may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words su…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On February 5, 2026, Doximity, Inc. (“Doximity” or the “Company”) announced that Anna Bryson, the Company’s Chief Financial Officer, principal financial officer, and principal accounting officer, is taking a temporary medical leave of absence. In connection with Ms. Bryson’s leave, effective February 3, 2026, the Company’s Board of Directors appoint…